IDH1 and central nervous system cancer: Additional studies have revealed frequent IDH1/2 mutations in a variety of human cancers, including 70%-80% of low-grade gliomas, 50%-70% of chondrosarcomas, 10–20% of intrahepatic cholangiocarcinoma and approximately 20% of acute myeloid leukemia (AML) [3, 7, 8].